Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1750P - Molecular genotyping in refractory thyroid cancers: Results of a European survey

Date

16 Sep 2021

Session

ePoster Display

Topics

Targeted Therapy

Tumour Site

Thyroid Cancer

Presenters

Christelle de la Fouchardiere

Citation

Annals of Oncology (2021) 32 (suppl_5): S1205-S1210. 10.1016/annonc/annonc715

Authors

C. de la Fouchardiere1, L. Fugazzola2, J. Taylor3, M. Appetecchia4, N. Besic5, A. Bongiovanni6, C. Buffet7, G. Costante8, S. Gay9, E. Grande10, E. Kapiteijn11, J. Krajewska12, M. Kroiss13, H. Morreau14, R. Netea-Maier15, R. Peeters16, P. Soares17, G. Sykiotis18, J. Blay19, L.D. Locati20

Author affiliations

  • 1 Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Division Of Endocrine And Metabolic Diseases, Ospedale San Luca, IRCCS Istituto Auxologico Italiano, Milan/IT
  • 3 Thyroid Cancer Alliance, Thyroid Cancer Alliance, Rotterdam/NL
  • 4 Endocrinology Department, Istituto Nazionale Tumori Regina Elena, 00144 - Rome/IT
  • 5 Department Of Surgical Oncology, Institute of Oncology, Ljubljana/SI
  • 6 Immunotherapy Unit, IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., 47014 - Meldola/IT
  • 7 Unité Thyroïde-tumeurs Endocrines, Hôpital Pitié Salpêtrière, Paris/FR
  • 8 Médecine Interne, Institut Jules Bordet, Bruxelles/BE
  • 9 Endocrinology Unit,, Policlinico San Martino, Genoa,/IT
  • 10 Medical Oncology Department, MD Anderson Cancer Center Madrid, 28033 - Madrid/ES
  • 11 Medical Oncology Dept., Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 12 Endocrinology Department, Maria Sklodowska-Curie Institute - Oncology Center (MSCI), Gliwice Branch, 44-101 - Gliwice/PL
  • 13 Endocinology, LMU Klinikum, Munchen/DE
  • 14 Pathology Department, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 15 Department Of Internal Medicine, Division Of Endocrinology, Radboud University Medical Center,, Nijmegen/NL
  • 16 Endocrinology Department, Erasmus Medisch Centrum, Rotterdam/NL
  • 17 Institute Of Molecular Pathology And Immunology, University of Porto, 4200-135 - Porto/PT
  • 18 Medicine, Service Of Endocrinology Department, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 19 Medicine Department, Centre Léon Bérard, 69008 - Lyon/FR
  • 20 Head And Neck Medical Oncology Unity, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
More

Abstract 1750P

Background

The management of radioiodine refractory -RAIR) thyroid cancers (TC), metastatic medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC) has recently changed with the arrival of new treatments that target specific molecular abnormalities. Differences in the ability to offer molecular somatic screening and targeted treatments can lead to disparities in cancer care among different European countries.

Methods

From Nov 18th 2020 to Jan 18th 2021, an online survey invitation was sent to EURACAN G6 Group, EORTC Endocrine Group and ETA members. It comprised 19 questions regarding country, medical practice modalities, molecular genotyping capacities, reimbursement and treatment access modalities.

Results

A total of 86 practitioners from 18 European Union countries (n=83), Switzerland (n=2) and Turkey (n=1) responded. Most were endocrinologists (47.7%) and worked in academic centres (57.1%). Forty-seven of them (44.2%) declared being routinely involved in managing aggressive TC including 38/47 (80.9%) regularly prescribing somatic molecular genotyping. The preferred methods were tumor DNA-based techniques for gene mutations (89.8%) and gene fusions (64.4%), which were mainly funded by national healthcare systems (73.7%). Among those not prescribing molecular analyses, main reasons were lack of reimbursement (46.7%), lack of established workflow (46.7%) and lack of access to targeted therapies (40%). The most frequently searched molecular alterations were BRAF mutations, RET and NTRK fusions in RAIR-TC, RET mutations in MTC, and BRAF mutations and NTRK fusions in ATC. Access to selective inhibitors is mainly driven by clinical trials, with routine-access to therapies being available in only 40% of the institutions.

Conclusions

This survey, examining molecular genotyping in aggressive TC, shows that most of the respondents regularly use gene sequencing in these rare cancers, even if selective targeted therapies are not easily and equally available throughout Europe. Clinical trials are important to facilitate access to innovative treatments in rare cancers. Collaboration with underrepresented European countries could be developed by scientific societies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

C. de la Fouchardiere: Financial Interests, Personal, Advisory Board, null: Merck; Financial Interests, Personal, Advisory Board, null: Roche; Financial Interests, Personal, Advisory Board, null: Lilly; Financial Interests, Personal, Advisory Board, null: Bayer; Financial Interests, Personal, Advisory Board, null: Amgen; Financial Interests, Personal, Advisory Board, null: MSD; Financial Interests, Personal, Advisory Board, null: Servier; Financial Interests, Personal, Invited Speaker, null: Ipsen; Financial Interests, Personal, Invited Speaker, null: Eisai; Financial Interests, Personal, Advisory Board, null: Pierre Fabre Oncologie; Financial Interests, Institutional, Invited Speaker, null: Pierre Fabre Oncologie; Financial Interests, Institutional, Invited Speaker, null: Servier. G. Costante: Financial Interests, Personal, Expert Testimony: Lilly. E. Grande: Financial Interests, Personal, Invited Speaker: Adacap; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Invited Speaker: Astra Zeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Institutional, Advisory Board: Caris Life Sciences; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: Eusa Pharma; Financial Interests, Personal, Invited Speaker: IPSEN; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Merck GA; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: ONCODNA; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Sanofi-Genzyme; Financial Interests, Institutional, Research Grant: Astellas; Financial Interests, Institutional, Research Grant: Astra Zeneca; Non-Financial Interests, Institutional, Other: Ipsen; Non-Financial Interests, Institutional, Invited Speaker: Lexicon; Non-Financial Interests, Institutional, Invited Speaker: MTEM/Threshold; Non-Financial Interests, Institutional, Research Grant: Nanostrinf Technologyes; Non-Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: Roche; Other, Personal, Member of the Board of Directors: ENETS. J. Blay: Financial Interests, Personal and Institutional, Research Grant: Roche; Financial Interests, Personal and Institutional, Research Grant: Bayer; Financial Interests, Personal and Institutional, Research Grant: Ignyta; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Ignyta. L.D. Locati: Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Merck Serono; Financial Interests, Personal, Invited Speaker: McCann Healthcare; Financial Interests, Personal, Invited Speaker: Biogene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.